• Novel Allosteric PDK4 Inhibitors Targeting Metabolic Dysregu

  2026-07-17

  Jeon et al. report the discovery of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, with lead compound 8c demonstrating nanomolar potency, metabolic stability, and efficacy in models of metabolic disease, allergy, and cancer. These findings offer a validated molecular scaffold for future therapeutic development targeting metabolic and proliferative disorders.

• Deep Learning of USC Mitochondria as Non-Invasive AD Biomark

  2026-07-17

  This study introduces a deep learning-based approach for analyzing mitochondrial morphology in urine-derived stem cells (USCs) as a non-invasive biomarker for Alzheimer’s disease. The method discriminates mitochondrial phenotypes associated with cognitive impairment, supporting new strategies for early detection and systemic monitoring of AD.

• Rotigotine: Advanced Dopaminergic Modulation in PD and RLS M

  2026-07-16

  Discover how Rotigotine, a potent dopamine D2/D3 receptor agonist, advances Parkinson's disease and restless legs syndrome research through continuous dopaminergic modulation and neuroprotective mechanisms. This article reveals unique protocol insights and translational considerations beyond conventional assay workflows.

• Ouabain (B2270): Precision Na⁺/K⁺-ATPase Inhibition in Cardi

  2026-07-16

  Explore how Ouabain, a selective Na+/K+-ATPase inhibitor, enables precise dissection of cardiac and cellular signaling mechanisms. This article offers advanced insights beyond typical workflows, including reference-backed analysis and unique assay considerations for cardiovascular research.

• n-Dodecyl-β-D-maltoside: Enabling Next-Gen Integrin Structur

  2026-07-15

  Explore how n-Dodecyl-β-D-maltoside advances structural biology by stabilizing challenging membrane proteins for high-resolution cryo-EM studies. This article reveals unique insights into integrin conformational diversity and practical assay design, setting it apart from standard purification guides.

• Lumiracoxib: Applied Workflows for Selective COX-2 Inhibitio

  2026-07-15

  Lumiracoxib empowers precise COX-2 pathway modulation in inflammation and muscle regeneration models, thanks to its high selectivity and robust solubility profile. This guide details optimized experimental workflows, troubleshooting tactics, and insights gained from recent advances in venom-induced muscle injury research.

• SOAT1 Inhibition Restores Lipophagy in PHMG-Induced Lung Fib

  2026-07-14

  This study identifies sterol O-acyltransferase 1 (SOAT1) as a pivotal mediator of pulmonary fibrosis caused by polyhexamethylene guanidine (PHMG) exposure. By revealing how SOAT1 upregulation in alveolar macrophages disrupts cholesterol homeostasis and blocks lipophagy, the research demonstrates that SOAT1 inhibition offers a promising therapeutic strategy for fibrotic lung disease.

• Guidelines for Diagnosis and Treatment of Cutaneous Candidia

  2026-07-14

  This article analyzes the 2009 guidelines for mucocutaneous candidiasis, highlighting the clinical classification, diagnostic methods, and the superior efficacy of imidazole antifungals such as neticonazole hydrochloride for topical management. The findings emphasize the importance of direct microscopic examination for diagnosis and the rationale for selecting specific antifungal agents in clinical and research settings.

• Guidelines for Mucocutaneous Candidiasis: Imidazole Antifung

  2026-07-13

  This article analyzes key innovations in the diagnosis and treatment of mucocutaneous candidiasis, focusing on the clinical evidence supporting imidazole antifungal agents. Drawing on recent guideline updates, it discusses diagnostic workflows, drug selection, and the rationale for topical therapy, with practical implications for translational and applied research.

• Luminescent ATP Detection Assay Kit: Precision in Cellular A

  2026-07-13

  The Luminescent ATP Detection Assay Kit by APExBIO enables ultra-sensitive, robust ATP measurement in complex cellular and tissue samples—without harsh extractions. Its stable luminescent signal and broad dynamic range streamline energy metabolism studies, even in models of mitochondrial dysfunction and apoptosis.

• ABT-888 (Veliparib): DNA Repair Inhibition for Cancer Resear

  2026-07-12

  ABT-888 (Veliparib) enables precise DNA repair inhibition, transforming colorectal and MSI tumor model workflows by enhancing chemotherapy and radiation responses. This guide delivers actionable protocols and troubleshooting strategies, with a direct translation of recent reference innovations into practical assay design.

• Cyclosporin A in Bench Research: Protocols & Troubleshooting

  2026-07-10

  Cyclosporin A is an indispensable tool in immunology, apoptosis, and mitochondrial research, enabling targeted inhibition of cyclophilins and calcineurin-NFAT signaling. This article delivers actionable protocols, troubleshooting insights, and bridges recent mechanistic advances from mitophagy studies, helping researchers maximize reproducibility and cross-domain insight.

• CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Ce

  2026-07-09

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit addresses the need for robust, long-term fluorescent cell labeling in cell proliferation and lineage tracing workflows. It is best suited for experiments requiring stable, covalent dye retention with minimal cytotoxicity, and should not be used for applications needing rapid dye clearance or reversible staining.

• Technical Guide: HyperPFU™ High-Fidelity DNA Polymerase in P

  2026-07-09

  HyperPFU™ high-fidelity DNA polymerase addresses the challenge of accurate PCR amplification for long, GC-rich, or otherwise difficult templates where standard polymerases show limited fidelity or processivity. It is best suited for workflows requiring blunt-ended, high-fidelity PCR products, but should not be used in protocols that require 3'-A overhangs or sticky ends.

• Strategic Modulation of cAMP Signaling: H-89 in Osteogenic R

  2026-07-08

  This thought-leadership article explores the pivotal role of H-89, a selective cAMP-dependent protein kinase inhibitor, in translating cutting-edge mechanistic discoveries in osteogenic signaling into actionable laboratory workflows. Drawing on recent findings in Wnt–O-GlcNAcylation-driven bone formation, it provides researchers with mechanistic context, protocol strategies, and translational insights, while positioning APExBIO's H-89 as a gold-standard tool for high-fidelity PKA inhibition.

451 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page